OncoSNIPE® artificial intelligence project officially launched

Newsletter IMODI 4 - October 2017
Discover and Share the Newsletter IMODI #4 – October 2017
Olivier DUCHAMP, IMODI coordinator, co-author of “PDX-MI Minimal Information for Patient-Derived Tumor Xenograft Models” publication

OncoSNIPE® artificial intelligence project officially launched

  • A structural competitiveness project (PSPC) under the “Investments for the Future Programme” coordinated by Oncodesign
  • Integration of UNICANCER, grouping together all the French Comprehensive Cancer Centres (FCCCs), into the consortium
  • Favorable opinion from the CPP (French Ethical Review Board) authorizing a longitudinal clinical trial in oncology

The decision by UNICANCER, which combines the 20 French Comprehensive Cancer Centres (FCCCs), to come on board has given the consortium partners access to ConSoRe, a digital 3.0 platform dedicated to cancer. ConSoRe will be significantly enriched by the OncoSNIPE partners through the anonymization of patient records, omic data integration from the clinical trial, identification of similar patients, creation of a link with the tranSMART precision medicine platform and, lastly, identification of patient populations resistant or unresponsive to cancer therapies..

« The aim is to improve modelling of resistance to oncology therapies through contextualization of clinical data, omics and imaging through the enrichment of relevant metadata from patient records » said Philippe Genne, Founder and CEO of Oncodesign. « Once this project has been completed, Oncodesign will be able to identify new targets to address treatment resistance and unresponsiveness, making it a powerful catalyst for our Discovery activities, through both partnerships and licensing programs. This technology is crucial for precision medicine, an area in which we are looking to expand very substantially in the coming years. »

« The OncoSNIPE project is highly innovative and holds out the promise of better care for patients who are resistant to classic therapies, » added Pascale Flamant, UNICANCER’s Managing Director. « “To complete this project, UNICANCER is delighted to be making its ConSoRe tool available to the Consortium, and it will in future permit its installation in healthcare establishments other than just the comprehensive cancer centres. »

The project has been approved by the North-West IV ethics review board, and so a longitudinal clinical trial can be set up enrolling 600 patients in lung cancer, breast cancer and pancreatic cancer—three cancer indications representing sources of resistance and unresponsiveness. This trial will study the molecular profiles associated with unresponsiveness to therapies in patients with these cancers.
Share this